Paragon Capital Management Ltd acquired a new position in Eli Lilly And Co (NYSE:LLY) during the first quarter, HoldingsChannel reports. The institutional investor acquired 1,693 shares of the company’s stock, valued at approximately $220,000.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Athena Capital Advisors LLC bought a new position in Eli Lilly And Co during the fourth quarter valued at approximately $26,000. Wakefield Asset Management LLLP bought a new position in Eli Lilly And Co during the fourth quarter valued at approximately $27,000. Larson Financial Group LLC bought a new position in Eli Lilly And Co during the fourth quarter valued at approximately $29,000. Ironwood Financial llc bought a new position in Eli Lilly And Co during the fourth quarter valued at approximately $30,000. Finally, Trust Department MB Financial Bank N A lifted its position in Eli Lilly And Co by 54.7% during the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after purchasing an additional 82 shares during the period. Institutional investors and hedge funds own 84.49% of the company’s stock.
In other Eli Lilly And Co news, insider Donald A. Zakrowski sold 1,000 shares of Eli Lilly And Co stock in a transaction on Friday, March 1st. The shares were sold at an average price of $127.01, for a total value of $127,010.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly And Co stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $122.48, for a total transaction of $25,108,400.00. Following the completion of the transaction, the insider now directly owns 117,641,684 shares of the company’s stock, valued at $14,408,753,456.32. The disclosure for this sale can be found here. Insiders have sold a total of 870,959 shares of company stock worth $109,672,752 over the last 90 days. Insiders own 0.11% of the company’s stock.
A number of research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday. TheStreet downgraded shares of Eli Lilly And Co from a “b+” rating to a “c+” rating in a research report on Thursday, May 9th. BMO Capital Markets increased their price objective on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Cantor Fitzgerald restated a “buy” rating and set a $143.00 price objective on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. Finally, Edward Jones upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective on the stock in a research report on Tuesday, April 23rd. Eleven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Eli Lilly And Co presently has a consensus rating of “Buy” and a consensus price target of $118.83.
LLY opened at $114.94 on Thursday. The company has a debt-to-equity ratio of 5.50, a quick ratio of 0.85 and a current ratio of 1.12. Eli Lilly And Co has a 1-year low of $80.96 and a 1-year high of $132.13. The company has a market capitalization of $111.03 billion, a price-to-earnings ratio of 20.71, a price-to-earnings-growth ratio of 2.03 and a beta of 0.27.
Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.01. The firm had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The company’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the firm earned $1.31 EPS. On average, equities analysts anticipate that Eli Lilly And Co will post 5.66 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Friday, May 17th will be given a dividend of $0.645 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $2.58 annualized dividend and a dividend yield of 2.24%. Eli Lilly And Co’s payout ratio is 46.49%.
COPYRIGHT VIOLATION WARNING: This piece was reported by Stock Observer and is owned by of Stock Observer. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.thestockobserver.com/2019/05/16/paragon-capital-management-ltd-acquires-new-holdings-in-eli-lilly-and-co-lly.html.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: What is Elliott Wave theory?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.